一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于重酒石酸利斯的 明口服溶液的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：重酒石酸利斯的明口服溶液 英文名/拉丁名：Rivastigmine Bitartrate Oral Solution 主要成份：重酒石酸利斯的明 剂 型：口服溶液剂 证券代码：300723 证券简称：一品红 公告编号：2025-079 一品红药业集团股份有限公司 关于全资子公司获得重酒石酸利斯的明口服溶液注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 注册分类：化学药品 3 类 规 格：120ml:0.24mg（按 C14H22N2O2计） 药品注册标准编号：YBH29112025 药品有效期：18 个月 申请事项：药品注册（境内生产） 包装规格： 1 瓶/盒 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 生产企业地址：广州市经济技术开发区东区东博路 6 号 药品批准文 ...

Core Viewpoint - Yipin Hong (300723) faces significant challenges with a high-profile lawsuit claiming 528 million yuan in damages, compounding its ongoing financial struggles and regulatory issues [1][4][8] Financial Performance - In 2024, Yipin Hong reported its first loss since going public, with revenue declining by 42.07% to 1.45 billion yuan and a net loss of 540 million yuan, compared to a profit of 185 million yuan the previous year [5][6] - For the first three quarters of 2025, the company generated revenue of 814 million yuan, a year-on-year decrease of 34.35%, and reported a net loss of 136 million yuan [7][8] Legal Issues - The lawsuit from Huiyou International claims infringement of a patent related to a joint project initiated in 2014, with Yipin Hong asserting that the patent rights belong to a joint venture and that it has the right to use the patent [2][3] - The total amount involved in other undisclosed lawsuits against Yipin Hong is approximately 5.63 million yuan, indicating ongoing legal challenges [3] Regulatory Challenges - In 2024, Yipin Hong's subsidiary was penalized for collusion in drug procurement, resulting in the cancellation of its qualification and a financial loss of 266 million yuan, which significantly impacted its financial performance [1][5][8] Strategic Outlook - The company is pinning hopes on the new gout drug AR882, which has completed its Phase III clinical trials, but faces uncertainties regarding clinical data, market competition, and commercialization capabilities [8]

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 182.83%, but a recent decline in the last 20 and 60 days, indicating potential market concerns [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002, with its IPO on November 16, 2017. The company focuses on the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The main revenue composition includes children's medicine (61.12%), chronic disease medicine (22.71%), and others (16.17%) [1]. Financial Performance - For the period from January to September 2025, Yipinhong reported operating revenue of 814 million yuan, a year-on-year decrease of 34.35%. The net profit attributable to the parent company was -136 million yuan, an increase of 44.80% year-on-year [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million yuan in dividends, with 151 million yuan distributed over the past three years [3]. Shareholder Information - As of October 31, 2025, Yipinhong had 20,700 shareholders, an increase of 9.42% from the previous period. The average circulating shares per person decreased by 8.61% to 20,156 shares [2]. - Notable new institutional shareholders include Hong Kong Central Clearing Limited, holding 4.1496 million shares, and several other funds entering the top ten circulating shareholders [3]. Market Activity - On November 19, Yipinhong's stock price fell by 2.01% to 48.25 yuan per share, with a trading volume of approximately 49.77 million yuan and a turnover rate of 0.24%. The total market capitalization is 21.794 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1].

Core Points - The company Yipinhong announced the election of Ms. Huang Liangwen as the employee director of the fourth board of directors [2] Summary by Category Company Announcement - Yipinhong has officially elected Ms. Huang Liangwen to serve as the employee director on its fourth board of directors [2]

Group 1 - The core point of the article is that Yipin Hong (SZ 300723) held its 13th meeting of the fourth board of directors on November 18, 2025, to discuss the election of new members for the remuneration and assessment committee [1] - As of the report, Yipin Hong has a market capitalization of 22.2 billion yuan [3] Group 2 - For the year 2024, Yipin Hong's revenue composition is as follows: 96.78% from pharmaceutical manufacturing and 3.22% from pharmaceutical agency [2]

Core Viewpoint - Yipin Pharmaceutical (300723.SZ) and its chairman Li Hanxiong are facing a lawsuit over intellectual property disputes, with the plaintiff seeking 528 million yuan in damages [1][2]. Group 1: Lawsuit Details - The lawsuit was filed by Huiyou International Limited against Yipin Pharmaceutical and its affiliates, including Li Hanxiong, for alleged breaches related to the joint development of "Prostaglandin E1 Liposome" [1][2]. - The original partnership was established 11 years ago, with both parties contributing to the development of the drug, which is used for various cardiovascular conditions [1]. - According to the cooperation agreement signed in October 2014, Yipin Pharmaceutical was to pay Huiyou International a total of 45 million yuan upon completion of certain milestones, including a 15 million yuan payment after patent transfer and a 30 million yuan payment after obtaining production approval [2]. Group 2: Financial Implications - Yipin Pharmaceutical reported a significant decline in revenue, with 2024 revenue at 1.45 billion yuan, down 42.07% year-on-year, and a net loss of 540 million yuan [4]. - In the first three quarters of 2025, the company continued to struggle, with revenue of 814 million yuan, a 34.35% decrease year-on-year, and a net loss of 136 million yuan [4]. Group 3: Market Context - Prostaglandin E1 injection is a major product in China's cardiovascular auxiliary medication market, with sales exceeding 10 billion yuan before 2018, although it has faced challenges due to national monitoring and procurement policies [3][4]. - Despite the challenges, the projected sales for the product in 2024 are estimated to be between 4 billion to 5 billion yuan [3].

Core Viewpoint - The company announced the resignation of non-independent director Yang Dongling due to adjustments in the corporate governance structure, but she will continue to hold other positions within the company [1] Group 1 - Yang Dongling submitted a written resignation report to the board, resigning from her position as a non-independent director and as a member of the Compensation and Assessment Committee [1] - The resignation will not affect the normal operation of the board, and it takes effect upon delivery to the board [1] - As of the date of the announcement, Yang Dongling does not hold any shares in the company and has no unfulfilled commitments [1]

证券代码：300723 证券简称：一品红 公告编号：2025-077 一品红药业集团股份有限公司 关于 2024 年员工持股计划第一个解锁期解锁条件成就的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）于 2025 年 11 月 18 日 召开第四届董事会第十三次会议和第四届监事会第十二次会议，审议通过了《关 于 2024 年员工持股计划第一个解锁期解锁条件成就的议案》，根据 2024 年员工 持股计划（草案）规定，第一个锁定期解锁条件已成就，可解锁的标的公司股票 数量为 1,534,831 股，占公司当前总股本的 0.34%。现将相关事项公告如下： 一、2024 年员工持股计划已履行的审批程序 1、2024 年 4 月 25 日，公司召开第三届董事会第二十二次会议和第三届监 事会第十八次会议，审议通过了《关于公司〈2024 年员工持股计划（草案）〉及 其摘要的议案》及相关议案。 因公司层面业绩考核未达成而未能解锁的份额，该份额对应标的股票由管理 委员会强制收回并择机出售，以该份额对应标的股票的实际出售金额与 ...

北京市中伦（广州）律师事务所 关于一品红药业集团股份有限公司 2024 年员工持股计划第一个锁定期 解锁条件成就相关事项的 法律意见书 二〇二五年十一月 北京市中伦（广州）律师事务所 关于一品红药业集团股份有限公司 2024 年员工持股计划 第一个锁定期解锁条件成就相关事项的 法律意见书 致：一品红药业集团股份有限公司 本所依据本法律意见书出具日以前已经发生或存在的事实和中国现行有效 的有关法律、法规、规范性文件及行业自律规则的规定发表法律意见。本所认定 某些事项是否合法有效是以该等事项发生之时所应适用的法律、法规、规范性文 1 法律意见书 件和行业自律规则为依据，同时也充分考虑了政府有关主管部门给予的有关批准 和确认。 在本法律意见书中，本所仅就公司本次员工持股计划本次解锁相关事项发表 法律意见，并不对有关会计、审计等专业事项发表评论。本所在本法律意见书中 对有关会计报表、审计报告中某些数据和结论的引述，并不意味着本所对该等数 据、结论的真实性和准确性做出任何明示或默示的保证，本所对于该等文件的内 容并不具备核查和作出评价的适当资格。 公司已向本所保证，其已提供了本所认为出具本法律意见书所必需的真实、 准确 ...

证券代码：300723 证券简称：一品红 公告编号： 2025-074 一品红药业集团股份有限公司 关于非独立董事辞职暨选举第四届董事会职工董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、非独立董事辞职情况 一品红药业集团股份有限公司（以下简称"公司"）董事会于近日收到非独 立董事杨冬玲女士的书面辞职报告，其因公司治理结构调整申请辞去公司第四届 董事会非独立董事职务以及薪酬与考核委员会委员，辞职后将继续在公司担任其 他职务。杨冬玲女士的辞职不会影响董事会的正常运作，其辞职报告自送达公司 董事会之日起生效。 黄良雯女士简历： 黄良雯，女，1976 年出生，中国国籍，无境外永久居留权，本科学历。曾 任公司第三、四届监事会监事，现任公司第四届董事会职工董事。黄良雯女士通 过持有广州市福泽投资管理中心（有限合伙）0.56%的出资份额间接持有公司股 份 135,000 股。黄良雯女士与公司控股股东、实际控制人不存在关联关系，与公 司董事、监事、高级管理人员及持有公司百分之五以上股份的股东之间亦不存在 关联关系。 黄良雯女士未受过中国证监会及其他有关部门的 ...